244 related articles for article (PubMed ID: 37401651)
21. Blood phenylalanine reduction reverses gene expression changes observed in a mouse model of phenylketonuria.
Manek R; Zhang YV; Berthelette P; Hossain M; Cornell CS; Gans J; Anarat-Cappillino G; Geller S; Jackson R; Yu D; Singh K; Ryan S; Bangari DS; Xu EY; Kyostio-Moore SRM
Sci Rep; 2021 Nov; 11(1):22886. PubMed ID: 34819582
[TBL] [Abstract][Full Text] [Related]
22. Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor.
Yin S; Ma L; Shao T; Zhang M; Guan Y; Wang L; Hu Y; Chen X; Han H; Shen N; Qiu W; Geng H; Yu Y; Li S; Yu W; Liu M; Li D
Sci China Life Sci; 2022 Apr; 65(4):718-730. PubMed ID: 32815069
[TBL] [Abstract][Full Text] [Related]
23. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria.
Rebuffat A; Harding CO; Ding Z; Thöny B
Hum Gene Ther; 2010 Apr; 21(4):463-77. PubMed ID: 19916803
[TBL] [Abstract][Full Text] [Related]
24. Modeling the cognitive effects of diet discontinuation in adults with phenylketonuria (PKU) using pegvaliase therapy in PAH-deficient mice.
Winn SR; Dudley S; Scherer T; Rimann N; Thöny B; Boutros S; Krenik D; Raber J; Harding CO
Mol Genet Metab; 2022 May; 136(1):46-64. PubMed ID: 35339387
[TBL] [Abstract][Full Text] [Related]
25. 5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics.
Levy H; Lamppu D; Anastosoaie V; Baker JL; DiBona K; Hawthorne S; Lindenberger J; Kinch D; Seymour A; McIlduff M; Watling S; Vockley J
Mol Genet Metab; 2020 Mar; 129(3):177-185. PubMed ID: 31883647
[TBL] [Abstract][Full Text] [Related]
26. Long-term correction of murine phenylketonuria by viral gene transfer: liver versus muscle.
Thöny B
J Inherit Metab Dis; 2010 Dec; 33(6):677-80. PubMed ID: 20151201
[TBL] [Abstract][Full Text] [Related]
27. Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing.
Brooks DL; Carrasco MJ; Qu P; Peranteau WH; Ahrens-Nicklas RC; Musunuru K; Alameh MG; Wang X
Nat Commun; 2023 Jun; 14(1):3451. PubMed ID: 37301931
[TBL] [Abstract][Full Text] [Related]
28. Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need.
Brooks DL; Whittaker MN; Qu P; Musunuru K; Ahrens-Nicklas RC; Wang X
Am J Hum Genet; 2023 Dec; 110(12):2003-2014. PubMed ID: 37924808
[TBL] [Abstract][Full Text] [Related]
29. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer.
Nagasaki Y; Matsubara Y; Takano H; Fujii K; Senoo M; Akanuma J; Takahashi K; Kure S; Hara M; Kanegae Y; Saito I; Narisawa K
Pediatr Res; 1999 Apr; 45(4 Pt 1):465-73. PubMed ID: 10203136
[TBL] [Abstract][Full Text] [Related]
30. Comparative metabolomics in the Pah
Dobrowolski SF; Phua YL; Sudano C; Spridik K; Zinn PO; Wang Y; Bharathi S; Vockley J; Goetzman E
Mol Genet Metab; 2022 May; 136(1):38-45. PubMed ID: 35367142
[TBL] [Abstract][Full Text] [Related]
31. Recovery of neurogenic amines in phenylketonuria mice after liver-targeted gene therapy.
Yagi H; Sanechika S; Ichinose H; Sumi-Ichinose C; Mizukami H; Urabe M; Ozawa K; Kume A
Neuroreport; 2012 Jan; 23(1):30-4. PubMed ID: 22107842
[TBL] [Abstract][Full Text] [Related]
32. Reversal of metabolic and neurological symptoms of phenylketonuric mice treated with a PAH containing helper-dependent adenoviral vector.
Cerreto M; Mehdawy B; Ombrone D; Nisticò R; Ruoppolo M; Usiello A; Daniele A; Pastore L; Salvatore F
Curr Gene Ther; 2012 Feb; 12(1):48-56. PubMed ID: 22348550
[TBL] [Abstract][Full Text] [Related]
33. Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy.
Oh HJ; Lee H; Park JW; Rhee H; Koo SK; Kang S; Jo I; Jung SC
Mol Genet Metab; 2005 Dec; 86 Suppl 1():S124-32. PubMed ID: 16150627
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Metabolic Correction of Phenylketonuria by AAV-Delivered Phenylalanine Amino Lyase.
Tao R; Xiao L; Zhou L; Zheng Z; Long J; Zhou L; Tang M; Dong B; Yao S
Mol Ther Methods Clin Dev; 2020 Dec; 19():507-517. PubMed ID: 33335942
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics and diagnosis of phenylketonuria: state of the art.
Blau N; Shen N; Carducci C
Expert Rev Mol Diagn; 2014 Jul; 14(6):655-71. PubMed ID: 24882081
[TBL] [Abstract][Full Text] [Related]
36. AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria.
Richards DY; Winn SR; Dudley S; Nygaard S; Mighell TL; Grompe M; Harding CO
Mol Ther Methods Clin Dev; 2020 Jun; 17():234-245. PubMed ID: 31970201
[TBL] [Abstract][Full Text] [Related]
37. The PAH gene, phenylketonuria, and a paradigm shift.
Scriver CR
Hum Mutat; 2007 Sep; 28(9):831-45. PubMed ID: 17443661
[TBL] [Abstract][Full Text] [Related]
38. Mesenchymal stem cell energy deficit and oxidative stress contribute to osteopenia in the Pah
Dobrowolski SF; Sudano C; Phua YL; Tourkova IL; Spridik K; Goetzman ES; Vockley J; Blair HC
Mol Genet Metab; 2021 Mar; 132(3):173-179. PubMed ID: 33602601
[TBL] [Abstract][Full Text] [Related]
39. A porcine model of phenylketonuria generated by CRISPR/Cas9 genome editing.
Koppes EA; Redel BK; Johnson MA; Skvorak KJ; Ghaloul-Gonzalez L; Yates ME; Lewis DW; Gollin SM; Wu YL; Christ SE; Yerle M; Leshinski A; Spate LD; Benne JA; Murphy SL; Samuel MS; Walters EM; Hansen SA; Wells KD; Lichter-Konecki U; Wagner RA; Newsome JT; Dobrowolski SF; Vockley J; Prather RS; Nicholls RD
JCI Insight; 2020 Oct; 5(20):. PubMed ID: 33055427
[TBL] [Abstract][Full Text] [Related]
40. PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) mice.
Embury JE; Charron CE; Martynyuk A; Zori AG; Liu B; Ali SF; Rowland NE; Laipis PJ
Brain Res; 2007 Jan; 1127(1):136-50. PubMed ID: 17112485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
